US4954526A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
Assignee: United States Department of Health and Human Services
•
Filing: 1989-02-28
•
Granted: 1990-09-04
•
Expires: 2009-02-28
Abstract
Abstract A method of treating cardiovascular disorders in a mammal, by administering to said mammal an effective amount of a compound of the formula: [R--N(H)N(NO)O--].sub.y X wherein R is loweralkyl, aryl, arylalkyl, or cycloalkyl, any of which R groups may be optionally substituted by one to three substituents selected from the group consisting of: halo, hydroxyl, alkoxy, amino, amido, formyl, carboxyl, or nitro; and wherein X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from loweralkyl, acyl or amido, and Y is 1 to 3 consistent with the valence of X. Pharmaceutical compositions containing the compounds are also provided.
Inventors
- 👤 Larry K. Keefer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 12:10
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K31/14; A61K31/655; A61K47/00; A61K47/50; A61K47/51; A61K47/54; A61P; A61P9/00; A61P9/08; A61P9/10; A61P9/12
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
125 words
A method of treating hypertension, wherein said method comprises administering to a mammal, in need thereof, a therapeutically effective amount of a compound of the formula: [R--N(H)N(NO)O--].sub.y X wherein: R is C 3-8 lower alkyl, phenyl, benzyl, or C 3-8 cycoloalkyl, any of which R groups may be substituted by one to three substituents, same or different, selected from the group consisting of halo, hydroxy, C 1-8 alkoxy, --NH 2 , --C(O)NH 2 , --CH(O), --C(O)OH and --NO 2 : X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C 1-8 lower alkyl, --C(O)CH 3 and --C(O)NH 2 ; and Y is one to three, consistent with the valence of X.
Claim 2
Independent Claim
125 words
A method of treating hypertension, wherein said method comprises administering to a mammal, in need thereof, a therapeutically effective amount of a compound of the formula: [R--N(H)N(NO)O--].sub.y X wherein: R is C 3-8 lower alkyl, phenyl, benzyl, or C 3-8 cycoloalkyl, any of which R groups may be substituted by one to three substituents, same or different, selected from the group consisting of halo, hydroxy, C 1-8 alkoxy, --NH 2 , --C(O)NH 2 , --CH(O), --C(O)OH and --NO 2 : X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C 1-8 lower alkyl, --C(O)CH 3 and --C(O)NH 2 ; and Y is one to three, consistent with the valence of X.
Claim 3
Dependent Claim
41 words
The method of claim 1, wherein R is branched chain lower alkyl group of 3-6 carbon length, optionally substituted by one to three substituents, same or different, selected from the group consisting of halo, --NH 2 , hydroxy, --CH(O) and --C(O)OH.
Claim 4
Dependent Claim
35 words
The method of claim 1, wherein R is C 3-8 cycloalkyl, optionally substituted by one to three substituents, same or different, selected from the group consisting of halo, --NH 2 , hydroxy, --CH(CO) and --C(O)OH.
Claim 5
Dependent Claim
9 words
The method of claim 1, wherein R is isopropyl.
Claim 6
Dependent Claim
13 words
The method of claim 1, wherein said compound is administered by intravenous injection.
Claim 7
Dependent Claim
18 words
The method of claim 1, wherein R is isopropyl; and wherein said compound is administered by intravenous injection.
Claim 8
Dependent Claim
12 words
The method of claim 1, wherein X is a pharmaceutically acceptable cation.
Claim 9
Dependent Claim
41 words
The method of claim 7, wherein R is branched chain lower alkyl group of 3-6 carbon length, optionally substituted by one to three substituents, same or different, selected from the group consisting of halo, --NH 2 , hydroxy, --CH(O) and --C(O)OH.
Claim 10
Dependent Claim
9 words
The method of claim 7, wherein R is isopropyl.
Claim 11
Dependent Claim
18 words
The method of claim 7, wherein R is isopropyl; and wherein said compound is administered by intravenous injection.
Claim 12
Dependent Claim
122 words
A pharmaceutical composition comprising: (I) a therapeutically effective hypertension treating amount of a compound of the formula: [R--N(H)N(NO)O--].sub.y X wherein: R is C 3-8 lower alkyl, phenyl, benzyl, or C 3-8 cycloalkyl, any of which R groups may be substituted by one to three substituents, same or different, selected from the group consisting of halo, hydroxy, C 1-8 alkoxy, --NH 2 , --C(O)NH 2 , --CH(O), --C(O)OH and --NO 2 : X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group, selected from the group consisting of C 1-8 lower alkyl, --C(O)CH 3 and --C(O)NH 2 ; Y is one to three, consistent with the valence of X; and (II) a pharmaceutically acceptable carrier therefor.
Claim 13
Dependent Claim
122 words
A pharmaceutical composition comprising: (I) a therapeutically effective hypertension treating amount of a compound of the formula: [R--N(H)N(NO)O--].sub.y X wherein: R is C 3-8 lower alkyl, phenyl, benzyl, or C 3-8 cycloalkyl, any of which R groups may be substituted by one to three substituents, same or different, selected from the group consisting of halo, hydroxy, C 1-8 alkoxy, --NH 2 , --C(O)NH 2 , --CH(O), --C(O)OH and --NO 2 : X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group, selected from the group consisting of C 1-8 lower alkyl, --C(O)CH 3 and --C(O)NH 2 ; Y is one to three, consistent with the valence of X; and (II) a pharmaceutically acceptable carrier therefor.
Claim 14
Dependent Claim
42 words
The composition of claim 11, wherein R is a branched chain lower alkyl group having 3-6 carbon length, optionally substituted by one to three substituents, same or different, selected from the group consisting of halo, hydroxyl, --NH 2 , --CH(O) and --C(O)OH.
Claim 15
Dependent Claim
35 words
The composition of claim 11, wherein R is C 3-8 cycolalkyl, optionally substituted by one to three substituents, same or different, selected from the group consisting of halo, --NH 2 , hydroxy, --CH(O), and --C(O)OH.
Claim 16
Dependent Claim
9 words
The composition of claim 11, wherein R is isopropyl.
Claim 17
Dependent Claim
13 words
The composition of claim 11, wherein said composition is suitable for intravenous injection.
Claim 18
Dependent Claim
17 words
The composition of claim 11, wherein R is isopropyl, and said composition is suitable for intravenous injection.
Claim 19
Dependent Claim
12 words
The composition of claim 11, wherein X is a pharmaceutically acceptable cation.
Claim 20
Dependent Claim
42 words
The composition of claim 17, wherein R is a branched chain lower alkyl group having 3-6 carbon length, optionally substituted by one to three substituents, same or different, selected from the group consisting of halo, hydroxyl, --NH 2 , --CH(O) and --(O)OH.
Claim 21
Dependent Claim
9 words
The composition of claim 17, wherein R is isopropyl.
Claim 22
Dependent Claim
13 words
The composition of claim 17, wherein said composition is suitable for intravenous injection.
References Cited (Backward Citations)
US2635978A
Cited
US2954314A
Cited
US3153094A
Cited
US3309373A
Cited
US3930970A
Cited
JPS62175613A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-09-03 | 1994-03-05 | 1994-09-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-09-03 | 1998-03-05 | 1998-09-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-09-03 | 2002-03-05 | 2002-09-04 | $7700.00 | Window Closed / Lapsed |